Last €10.09 EUR
Change Today -0.229 / -2.22%
Volume 0.0
B9M On Other Exchanges
As of 10:24 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

btg plc (B9M) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/4/14 - €10.56
52 Week Low
04/15/14 - €5.84
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BTG PLC (B9M)

Related News

No related news articles were found.

btg plc (B9M) Related Businessweek News

No Related Businessweek News Found

btg plc (B9M) Details

BTG plc, a specialist healthcare company, develops and commercializes products targeting critical care, cancer, and varicose veins. It operates through three segments: Specialty Pharmaceuticals, Interventional Medicine, and Licensing & Biotechnology. The company markets and sells specialty pharmaceuticals, including CroFab, a treatment for patients bitten by North American pit vipers; DigiFab, a treatment for patients suffering toxicity associated with the use of the heart medicine digoxin; and Voraxaze, a treatment for toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function. It also offers a range of interventional oncology products comprising Bead Block, TheraSphere, LC Bead, and DC Bead used to treat patients with hypervascularized tumors; and EkoSonic Endovascular System for the treatment of patients with severe blood clots, and Varithena polidocanol injectable foam for the treatment for patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. The company’s products in late-stage development include TheraSphere in Phase 3 clinical trials in hepatocellular carcinoma (HCC) and 2nd line metastatic colorectal cancer (mCRC); Beads in investigator-initiated/registration studies in HCC and 3rd line mCRC; and Uridine triacetate in development with Wellstat Therapeutic Corporation as a treatment for toxicity associated with the use of the chemotherapeutic 5-fluorouracil. The company’s licensing products comprise Zytiga, a treatment for patients with prostate cancer; Two-Part Hip Cup, a prosthetic hip joint replacement licensed to hip-replacement technology manufacturers; and Lemtrada, a treatment for patients with relapsing-remitting multiple sclerosis. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.

860 Employees
Last Reported Date: 06/16/14
Founded in 1948

btg plc (B9M) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 1.0M GBP
Chief Financial Officer, Executive Director a...
Total Annual Compensation: 657.0K GBP
Compensation as of Fiscal Year 2014.

btg plc (B9M) Key Developments

BTG plc Appoints Susan Foden as Non-Executive Director of the Board, Effective March 1, 2015

BTG plc announced the appointment of Dr. Susan Foden as a non-executive director of the Board, effective from March 1, 2015. She is currently Chair of BerGenBio AS and Cizzle Biotech Ltd, holds non-executive roles with Vectura Group plc, Evgen Ltd, Source Bioscience plc and is an advisory board member for CD3 (a joint initiative between Leuven University and the European Investment Fund).

BTG plc, PneumRx, Inc. - M&A Call

To acquire the PneumRx, Inc

BTG plc Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 09:20 AM

BTG plc Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 09:20 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
B9M:GR €10.09 EUR -0.229

B9M Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hikma Pharmaceuticals PLC 2,032 GBp -11.00
Impax Laboratories Inc $31.32 USD +0.54
Merit Medical Systems Inc $16.80 USD -0.23
Pfizer Ltd/India 2,051 INR +50.45
RPX Corp $14.16 USD +0.47
View Industry Companies

Industry Analysis


Industry Average

Valuation B9M Industry Range
Price/Earnings 71.5x
Price/Sales 8.6x
Price/Book 4.8x
Price/Cash Flow 44.8x
TEV/Sales 9.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BTG PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at